Drug Profile
Research programme: peptide therapeutics - Pfizer/Sutro Biopharma
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Sutro Biopharma
- Developer Pfizer; Sutro Biopharma
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in USA
- 07 Jan 2011 Early research in Undefined indication in USA (unspecified route)